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Medieval alchemists, craving the boon of youth and 
desiring renewed health and strength, were kept busy 
searching for the mythical elixir of life, a universal 
medicine supposedly containing a recipe for 
rejuvenescence. Now, in the 21
st century, their modern 
successors use the fruits of the genomics revolution to 
discover genetic factors that ward off aging and aging-
related diseases. In this issue of Aging, Gravina et al. 
[1]  present evidence that the long life span of the more 
fortunate among us could be related to variants of the 
p21 cell cycle inhibitor. 
 
Longevity is simply defined as the property of being 
long-lived, i.e., approaching the life span of the oldest 
individual of a species or a population. The latter is also 
called ‘maximum life span’, which in contrast to life 
expectancy (mean age at death in a population) is not 
greatly influenced by environmental conditions. 
Longevity is attained by keeping aging at bay. Aging 
can be defined operationally as a time-dependent loss of 
fitness that begins to manifest after the organism attains 
its maximum reproductive competence. Unlike 
longevity, this loss of fitness cannot easily be caught in 
some simple measurement. There are no real 
biomarkers for aging and its phenotype is extremely 
complex. 
 
The large variation in maximum life span among 
species points toward genetic factors that specify the 
mechanisms that protect against aging and disease. The 
identification of these genetic factors is of interest since 
they would provide targets for modes of prevention  and  
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intervention, eventually offering everybody a long and 
healthy life. In short-lived, model organisms such as 
worms and flies, multiple loci have been demonstrated 
to affect longevity as a genetic trait. Indeed, specific 
mutations in genes participating in pathways that are 
involved in growth and reproduction were shown to 
confer significant extension of the natural life span of 
these species [2]. Unfortunately, since little is known 
about the aging phenotypes that emerge over time to 
inexorably limits longevity in these species it has been 
difficult to extrapolate these results to humans. Hence, 
new model systems need to be found that provide more 
immediate links to human longevity and healthy aging. 
Thus far, humans themselves have provided the best 
such model system.   
 
With the passing of the years, genetic factors play an 
increasingly important role as determinants of lifespan. 
At the extreme end of this spectrum we find 
centenarians, people who attained the age of 100 years 
or more. This is unusual because current life 
expectancies are in the range of 70-80, at best. 
Centenarians escape the most common age-related 
diseases, which may be why they are exceptionally 
long-lived individuals [3]. However, it is also possible 
that they avoid or delay disease because of an inherently 
slower rate of intrinsic aging. In particular, cancer is 
absent or significantly delayed in centenarians and it is 
not at all unlikely that genetic variation at the loci that 
control tumorigenesis distinguish centenarians from 
their less fortunate brethren. Gravina et al. [1] put this 
hypothesis to the test by genotyping a population of 
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single nucleotide variation in the p21 gene [1]. The 
results revealed at least two rare variants, one in the 
coding regions leading to an amino acid subs-titution 
and another in the 3’-untranslated region, that were 
significantly under-represented among the centenarians. 
As argued by the authors, these p21 alleles may be 
detrimental to longevity and therefore negatively selected 
in centenarians. The question remains, how do these 
variants affect p21 functioning and what is the role if 
any of p21 in determining human life span? The authors 
consider the possibility that the identified rare alleles 
increase cancer risk and that their absence would 
increase the chance to live a cancer-free and therefore 
long life. This is plausible, but other scenarios are 
possible. 
 
The cyclin-dependent kinase inhibitor p21
WAF1/CIP1 is 
oneof the downstream targets of p53, the so-called 
guardian of the genome [4]. However, p21 is not as 
critical a tumor suppressor as p53. Unlike p53, few, if 
any, p21 mutations have been found in human tumors 
and p21 knockout mice do not develop many more 
spontaneous malignancies than their wildtype 
littermates [5]. Interestingly, evidence has been found 
that loss of p21 enhances survival of mice with a 
telomere dysfunction [6]. Hence, p21 may be a 
promoter of aging, and as such possibly the effector of 
the pro-aging characteristics of p53 [7]. Constitutive 
activation of p53 has been demonstrated as a likely 
cause of premature aging in a number of different 
mouse models, including animals expressing truncated 
p53 isoforms [8]. It is possible that one could retain 
tumor suppressing capability through p53 while 
simultaneously opposing its pro-aging activity through 
inhibition of p21 (Figure 1). 
 
Based on the above, it is conceivable that variations in 
p21 may affect its dual role in aging and cancer, shifting 
the balance to its pro-aging capacity while retaining 
robust tumor suppression. If followed up by functional 
studies, the SNP variants discovered by Gravina et al. 
could be an important step on our way to developing 
interventions to blunt p53’s pro-aging actions while 
retaining its anti-aging effects.  
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Figure 1. SNP variants in the p21 gene may attenuate the 
pro‐aging  activities  of  p53  without  increasing  genome 
instability and cancer. 
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